Short Interest in GeoVax Labs Inc. (NASDAQ:GOVX) Rises By 112.3%

GeoVax Labs Inc. (NASDAQ:GOVX) was the recipient of a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 321,661 shares, a growth of 112.3% from the January 15th total of 151,504 shares. Based on an average trading volume of 201,570 shares, the days-to-cover ratio is presently 1.6 days. Currently, 18.7% of the company’s stock are sold short. Currently, 18.7% of the company’s stock are sold short. Based on an average trading volume of 201,570 shares, the days-to-cover ratio is presently 1.6 days.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on GOVX. Wall Street Zen lowered shares of GeoVax Labs to a “strong sell” rating in a research report on Saturday, January 17th. D. Boral Capital reiterated a “buy” rating on shares of GeoVax Labs in a research note on Wednesday, January 21st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of GeoVax Labs in a research note on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $187.50.

GeoVax Labs Stock Performance

Shares of GeoVax Labs stock traded down $0.63 on Friday, reaching $1.68. The stock had a trading volume of 619,132 shares, compared to its average volume of 134,132. The business’s 50-day moving average price is $4.40 and its two-hundred day moving average price is $11.40. The stock has a market cap of $2.91 million, a P/E ratio of -0.05 and a beta of 3.77. GeoVax Labs has a fifty-two week low of $1.63 and a fifty-two week high of $47.13.

GeoVax Labs (NASDAQ:GOVX) last announced its earnings results on Thursday, November 13th. The company reported ($7.75) EPS for the quarter, missing the consensus estimate of ($6.00) by ($1.75). GeoVax Labs had a negative return on equity of 489.67% and a negative net margin of 403.88%. As a group, equities analysts forecast that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GOVX. Jane Street Group LLC acquired a new position in shares of GeoVax Labs during the first quarter worth approximately $27,000. HRT Financial LP bought a new position in GeoVax Labs during the fourth quarter worth $31,000. Hudson Bay Capital Management LP acquired a new position in GeoVax Labs during the 3rd quarter valued at $47,000. Renaissance Technologies LLC bought a new stake in GeoVax Labs in the 4th quarter valued at $104,000. Finally, Armistice Capital LLC acquired a new stake in GeoVax Labs in the 3rd quarter worth $253,000. 6.09% of the stock is owned by institutional investors.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.